As of June 1, 2025, La Jolla Pharmaceutical Co (LJPC) reports a Forward P/E of 12.08.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing La Jolla Pharmaceutical Co's Forward P/E to Peers
To better understand La Jolla Pharmaceutical Co's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| La Jolla Pharmaceutical Co (LJPC) | 12.08 |
| ADMA Biologics Inc (ADMA) | 29.76 |
| Covalon Technologies Ltd (COV.V) | 27.23 |
| Vertex Pharmaceuticals Inc (VRTX) | 24.20 |
| Abbvie Inc (ABBV) | 14.75 |
| Amgen Inc (AMGN) | 13.70 |
Compared to its competitors, La Jolla Pharmaceutical Co's Forward P/E is lower than all peers, which may suggest undervaluation or market concerns about future earnings.